.png)
NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NUVAXOVID is approved for use in individuals who are:
- 65 years of age and older, or
- 2 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
Are your patients concerned about COVID-19 vaccine side effects?
Concerns about COVID‑19 vaccine side effects may be stopping some patients from getting protected.2*
.png)
DO YOUR THING WITH NUVAXOVID: THE ONLY non-mRNA COVID-19 VACCINE WITH MANAGEABLE SIDE EFFECTS1,3†
With NUVAXOVID, you can feel confident in offering your patients the choice of a familiar, protein-based vaccine technology for their updated COVID-19 protection.1,4
NUVAXOVID IS THE ONLY non-mRNA, PROTEIN-BASED COVID-19 VACCINE1,3
- Proven ~90% effective against COVID-19 illness in the pivotal trial1,5‡
- 100% protection against severe disease shown in pivotal trial1,4§
- Low reactogenicity: in clinical trials the majority of patients reported no disruption to daily activities1†
.png)
*In a 2024 US survey, nearly half of participants stated they were not planning on getting an updated COVID-19 booster, of whom 56% cited concerns about side effects.2
†The majority of adverse events in clinical trials were Grade 1 or 2 and did not prevent daily activities. In clinical trials, most common side effects were mild to moderate and of short duration.1
‡Primary endpoint of efficacy against symptomatic lab–confirmed COVID-19 occurring at least 7 days after the second dose (95% CI: 82.5, 93.8; P<0.001).1,5
§Secondary endpoint of efficacy in preventing moderate-to-severe disease from then-circulating strains of virus. NUVAXOVID may not protect all vaccine recipients (95% CI: 87.0, 100.0).1,5
Learn about the ONLY FDA-approved, non-mRNA COVID-19 vaccine1,3
Protect your patients against COVID-19, severe illness, and hospitalization1,5,6
Offer NUVAXOVID to help provide protection with minimal disruption1
INDICATION
References
1. NUVAXOVID. Prescribing Information. Novavax, Inc. 2. National Foundation for Infectious Diseases. 2024 National Survey: attitudes and behaviors about influenza, COVID-19, respiratory syncytial virus, and pneumococcal disease. September 2024. Accessed January 28, 2025. https://www.nfid.org/ resource/2024-national-survey-attitudes-and-behaviors-about-influenza-covid-19-respiratory-syncytial-virus-and-pneumococcal-disease/ 3. Panagiotakopoulos L, Moulia DL, Godfrey M, et al. Use of COVID-19 vaccines for persons aged ≥6 months: recommendations of the Advisory Committee on Immunization Practices—United States, 2024-2025. MMWR Morb Mortal Wkly Rep. 2024 Sep 19;73(37):819-824. doi:10.15585/mmwr.mm7337e2 4. Centers for Disease Control and Prevention. Understanding How COVID-19 Vaccines Work. May 2023. Accessed August 8, 2025. https://archive.cdc.gov/www_cdc_gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html 5. Dunkle LM, Kotloff KL, Gay CL, et al; 2019nCoV-301 Study Group. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386(6):531-543. doi:10.1056/NEJMoa2116185 6. Marchese AM, Zhou X, Kinol J, et al. NVX-CoV2373 vaccine efficacy against hospitalization: a post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial. Vaccine. 2023;41(22):3461-3466. doi:10.1016/j.vaccine.2023.04.054
